司美格鲁肽 Semaglutide

Semaglutide is the most clinically validated weight loss drug currently available — and it's not particularly close. In the STEP 1 trial, patients on the 2.4 mg weekly dose lost an average of 14.9% of their body weight over 68 weeks.^[1] That's a number that, before this drug class, was only achievable with bariatric surgery.

It's a 31-amino acid GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1 (GLP-1), a hormone your gut releases after you eat. Semaglutide was engineered specifically for once-weekly dosing — a structural modification over its predecessor liraglutide that dramatically extended its half-life by increasing albumin binding affinity and protecting it from enzymatic degradation.^[2] That weekly dosing schedule is one reason adherence is so much better than older daily injectables.

Three branded formulations exist: Ozempic (subcutaneous injection, approved for type 2 diabetes), Wegovy (subcutaneous injection, approved for chronic weight management at a higher 2.4 mg dose), and Rybelsus (oral tablet, approved for type 2 diabetes). Same molecule, different doses and delivery systems, different approved indications.

• Semaglutide is FDA-approved for both type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy) — one of the few drugs with major approvals in both categories.

The escalation protocol exists for one reason: nausea. Your GI tract needs time to adapt to GLP-1 receptor activation. Starting at the maintenance dose would make most people miserable for weeks. The standard Wegovy escalation looks like this:

Wegovy Escalation Schedule — Approved Protocol

If you can't tolerate a dose increase, staying at the previous dose for an extra four weeks is standard practice — the escalation schedule is a guideline, not a hard rule. Some patients take six months to reach 2.4 mg. That's fine.

The STEP 1 trial used this 2.4 mg maintenance dose and ran for 68 weeks in adults with a BMI (body mass index) of 30 or higher, or 27+ with at least one weight-related condition.^[1]

For type 2 diabetes management with Ozempic, the typical maintenance dose is 0.5 mg to 1 mg weekly, with a 2 mg dose available for patients who need additional glycemic control. The SUSTAIN trial program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) established the efficacy and safety profile across this dose range.^[3]

Before semaglutide, weight loss drugs were measured in single-digit percentages. Orlistat produced around 3% placebo-adjusted weight loss. Phentermine-topiramate did better, but came with significant neuropsychiatric side effects and a contraindication in pregnancy. The bar was low.

Semaglutide cleared it by a wide margin. 14.9% average weight loss in STEP 1 means roughly one in three patients lost more than 20% of their body weight.^[1] That's not a modest metabolic nudge — that's a meaningful shift in disease trajectory for someone with obesity-related hypertension, sleep apnea, or pre-diabetes.

The cardiovascular data matters here

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) demonstrated that 2.4 mg weekly semaglutide reduced major adverse cardiovascular events by 20% in people with established cardiovascular disease and overweight or obesity — without diabetes as an entry criterion. This was the first weight loss drug to show a cardiovascular mortality benefit in a dedicated outcomes trial.

The other differentiator is the oral formulation. Rybelsus (14 mg oral) was the first oral GLP-1 agonist approved anywhere in the world. It's less effective than the injectable for weight loss — partly bioavailability, partly the lower approved dose — but for patients who can't or won't inject, it's a real option for glycemic control.

The starting point is GLP-1 itself. Your gut releases GLP-1 within minutes of eating, and it does several things at once: it tells your pancreas to release insulin (but only when blood glucose is elevated, which is why it doesn't cause hypoglycemia in non-diabetics), it signals the brain's hypothalamus to reduce appetite, and it slows the rate at which your stomach empties into the small intestine.

The problem with natural GLP-1 is that it has a half-life of about two minutes. Enzymes called DPP-4 break it down almost immediately. Semaglutide was engineered to solve exactly this problem.

The structural modifications that make semaglutide work as a once-weekly drug are specific: a substitution at position 8 of the peptide chain (replacing alanine with 2-aminoisobutyric acid) blocks DPP-4 from degrading it, and a C-18 fatty diacid chain attached via a linker to lysine at position 26 gives it extremely high albumin binding affinity.^[2] When semaglutide circulates in your blood, it's mostly bound to albumin — a large plasma protein that can't be filtered by the kidneys or rapidly cleared. That binding is what stretches a 2-minute half-life into ~7 days.

Once bound to GLP-1 receptors (GLP-1R), semaglutide activates pathways in the hypothalamus and brainstem that reduce hunger and increase satiety signals. This isn't just peripheral — there's meaningful CNS activity. Patients often describe not just feeling full faster, but genuinely caring less about food. The "food noise" reduction is something a lot of patients mention unprompted, and there's growing mechanistic evidence for why: GLP-1 receptors in the reward and motivation circuits of the brain appear to modulate dopaminergic responses to food cues.^[3]

Weight Management — The STEP Trials

The STEP program (Semaglutide Treatment Effect in People with Obesity) was a series of Phase 3 trials that established the weight loss profile of 2.4 mg weekly semaglutide.

STEP 1 enrolled 1,961 adults with obesity or overweight plus a weight-related condition, randomized to 2.4 mg semaglutide or placebo over 68 weeks.^[1] The 14.9% mean weight loss in the semaglutide group versus 2.4% in the placebo group is the headline number — but the distribution matters too. About 86% of semaglutide-treated patients lost at least 5% of body weight, and roughly 32% lost more than 20%.^[1] That spread tells you this isn't a drug that produces modest uniform results; some patients respond dramatically.

Type 2 Diabetes — The SUSTAIN Trials

The SUSTAIN trial program evaluated semaglutide across multiple comparators in type 2 diabetes management. SUSTAIN-6, the cardiovascular outcomes trial, randomized 3,297 patients with type 2 diabetes and high cardiovascular risk to semaglutide versus placebo over 104 weeks.^[3] The primary cardiovascular endpoint (major adverse cardiac events — heart attack, stroke, or cardiovascular death) was reduced by 26% in the semaglutide group.^[3] HbA1c (a 90-day average of blood glucose levels) dropped by 1.1 percentage points at 0.5 mg and 1.4 percentage points at 1.0 mg — clinically meaningful reductions for patients with type 2 diabetes.^[3]

Head-to-Head: Semaglutide vs. Tirzepatide

A 2024 real-world analysis published in JAMA Internal Medicine compared semaglutide and tirzepatide in adults with overweight or obesity — the first large head-to-head comparison in a non-diabetic population.^[4] Tirzepatide produced greater weight loss at 12 months (approximately 15.3% vs. 8.3% for semaglutide in that dataset).^[4] This isn't a randomized controlled trial, so confounders exist — but the direction of the finding aligns with the Phase 3 randomized trial data, where tirzepatide's 22.5% weight loss in SURMOUNT-1 exceeded semaglutide's STEP 1 results.^[4]

That said, semaglutide has a longer track record, more cardiovascular outcomes data, and broader insurance coverage in most markets. The "best" drug depends on your starting point, your goals, and what your insurance will actually cover.

• Long-term weight maintenance after stopping — Weight regain after discontinuation is substantial. A 2022 withdrawal study showed participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide. This drug appears to require ongoing use to maintain its effects, which has real implications for cost and access planning.
• Direct head-to-head RCT data against tirzepatide for weight loss — The JAMA Internal Medicine 2024 analysis was observational, not randomized.^[4] A proper head-to-head RCT hasn't been completed. Cross-trial comparisons are imprecise.
• Efficacy in patients without obesity — Most trial data is in patients with BMI ≥ 27 or ≥ 30. Using semaglutide for cosmetic weight loss in people with healthy BMIs is off-label and has no RCT support.
• Long-term safety beyond ~5 years — The longest trials run approximately 2 years. We don't have a 10-year safety dataset. The theoretical thyroid C-cell tumor risk (observed in rodents at high doses) has not been demonstrated in humans, but the observation period is still relatively short.^[3]
• Muscle mass preservation — GLP-1 agonists produce weight loss that includes lean mass loss, not just fat. The proportion varies by diet and exercise habits. There's no strong RCT evidence that semaglutide preserves lean mass better than other caloric-restriction approaches.

During dose escalation (weeks 1–16 or so):

• Nausea — the most common complaint, reported by a meaningful proportion of patients in clinical trials.^[3] It's worst in the 24–48 hours after each injection and typically improves as your body adapts. Eating smaller meals, avoiding high-fat foods around injection day, and staying hydrated all help.
• Vomiting — less common than nausea, but reported. If you're vomiting after every dose increase, that's a signal to hold the current dose longer before escalating.
• Diarrhea — tends to appear early in treatment and often resolves within a few weeks.

At stable dose:

• Constipation — more common at higher doses and later in treatment. The slowing of gastric motility that makes you feel full longer also slows the whole GI tract. Adequate fiber and hydration help significantly.
• Injection site reactions — mild redness or tenderness at the injection site; rotate between the abdomen, thigh, and upper arm to reduce this.
• Fatigue — reported by some patients, particularly during escalation. Usually transient.

Rare but worth knowing:

• Pancreatitis — a class-level concern for all GLP-1 agonists. The absolute risk appears low based on trial data, but if you develop severe, persistent abdominal pain, stop the medication and seek evaluation promptly.^[3]
• Thyroid C-cell tumors — observed in rodent studies at high doses; not demonstrated in human trials to date, but semaglutide carries a black-box warning and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.^[3]
• Gastroparesis — severe gastric motility slowing has been reported, particularly at higher doses. This is distinct from the normal mild slowing and warrants medical evaluation.

If you experience severe abdominal pain, persistent vomiting that prevents you from keeping down food or water, or signs of an allergic reaction (rash, difficulty breathing, swelling), contact your prescribing provider the same day — don't wait for your next scheduled appointment.

FDA approval status — as of 2026-03

Semaglutide is FDA-approved under three brand names: Ozempic (subcutaneous injection, 0.5 mg, 1 mg, 2 mg — type 2 diabetes), Wegovy (subcutaneous injection, 2.4 mg — chronic weight management in adults and adolescents 12+), and Rybelsus (oral tablet, 7 mg and 14 mg — type 2 diabetes). All three require a valid prescription from a licensed US healthcare provider.

Compounding status has changed significantly

During the 2022–2024 period when Ozempic and Wegovy were on the FDA drug shortage list, licensed 503A and 503B compounding pharmacies could legally produce semaglutide copies. In early 2025, FDA removed semaglutide from the shortage list. This triggered a wind-down period for compounders, and by mid-2025 the FDA had moved to restrict most compounding of commercially available semaglutide formulations. If you're currently receiving compounded semaglutide, verify your pharmacy's current legal status with your prescribing provider. Access through compounders is no longer broadly available the way it was in 2023–2024.

For most patients, the practical access pathway is: get a prescription from a licensed provider (primary care physician, endocrinologist, obesity medicine specialist, or a telehealth platform that prescribes weight loss medications), fill it at a retail or specialty pharmacy, and navigate insurance coverage. Prior authorization requirements are common for Wegovy; Ozempic is more frequently covered for patients with a type 2 diabetes diagnosis.

If you're looking for a clinic that prescribes semaglutide, the MyPeptideMatch clinic finder lets you filter by treatment category and location.

If you're evaluating semaglutide, the two most relevant comparisons are tirzepatide (Mounjaro/Zepbound) and liraglutide (Victoza/Saxenda). Liraglutide is semaglutide's predecessor — a once-daily GLP-1 agonist that produces roughly 5–8% weight loss, meaningfully less than semaglutide's 14.9% at the weight management dose. Tirzepatide adds GIP receptor agonism to the GLP-1 mechanism and has produced stronger weight loss numbers in trials, at the cost of being newer with less long-term safety and cardiovascular outcomes data.

For patients interested in where the GLP-1 class is heading, retatrutide is a triple agonist (GLP-1 + GIP + glucagon) currently in Phase 3 trials with Phase 2 data showing up to 24.2% weight loss — but it has no FDA approval and no commercial access yet.

GLP-1 Class Comparison: Semaglutide vs. Tirzepatide vs. Liraglutide